HRP20110791T1 - Derivati 1-tio-d-glucitola - Google Patents
Derivati 1-tio-d-glucitola Download PDFInfo
- Publication number
- HRP20110791T1 HRP20110791T1 HR20110791T HRP20110791T HRP20110791T1 HR P20110791 T1 HRP20110791 T1 HR P20110791T1 HR 20110791 T HR20110791 T HR 20110791T HR P20110791 T HRP20110791 T HR P20110791T HR P20110791 T1 HRP20110791 T1 HR P20110791T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkyl group
- halogen atom
- substituents selected
- compound
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 221
- 150000001875 compounds Chemical class 0.000 claims abstract 72
- 150000003839 salts Chemical class 0.000 claims abstract 52
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 37
- 229960002920 sorbitol Drugs 0.000 claims abstract 26
- 125000005843 halogen group Chemical group 0.000 claims 129
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 102
- 125000001424 substituent group Chemical group 0.000 claims 81
- 125000003710 aryl alkyl group Chemical group 0.000 claims 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 30
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 19
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000003944 tolyl group Chemical group 0.000 claims 8
- -1 benzo[b]thiophenyl group Chemical group 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 claims 5
- 229910006069 SO3H Inorganic materials 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- OROGUZVNAFJPHA-UHFFFAOYSA-N 3-hydroxy-2,4-dimethyl-2H-thiophen-5-one Chemical compound CC1SC(=O)C(C)=C1O OROGUZVNAFJPHA-UHFFFAOYSA-N 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 101100478314 Caenorhabditis elegans sre-1 gene Proteins 0.000 claims 2
- 239000007818 Grignard reagent Substances 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 150000004795 grignard reagents Chemical class 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- QRZLMTHXVLKGAR-ADAARDCZSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethylphenyl)methyl]phenyl]-6-(hydroxymethyl)thiane-3,4,5-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=CC=C1Cl QRZLMTHXVLKGAR-ADAARDCZSA-N 0.000 claims 1
- QQACZFXUTHECAN-OBKDMQGPSA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-methylphenyl)methyl]phenyl]-6-(hydroxymethyl)thiane-3,4,5-triol Chemical compound C1=CC(C)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=CC=C1Cl QQACZFXUTHECAN-OBKDMQGPSA-N 0.000 claims 1
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 claims 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
- 102000004366 Glucosidases Human genes 0.000 claims 1
- 108010056771 Glucosidases Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 claims 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 230000001539 anorectic effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000000841 delta opiate receptor agonist Substances 0.000 claims 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 1
- 125000004957 naphthylene group Chemical group 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 125000005551 pyridylene group Chemical group 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 230000000707 stereoselective effect Effects 0.000 claims 1
- 125000005556 thienylene group Chemical group 0.000 claims 1
- 125000005730 thiophenylene group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005002913 | 2005-01-07 | ||
| JP2005233912 | 2005-08-12 | ||
| PCT/JP2006/300135 WO2006073197A1 (fr) | 2005-01-07 | 2006-01-10 | Derives de 1-thio-d-glucitol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110791T1 true HRP20110791T1 (hr) | 2011-11-30 |
Family
ID=36647674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110791T HRP20110791T1 (hr) | 2005-01-07 | 2011-10-28 | Derivati 1-tio-d-glucitola |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7910619B2 (fr) |
| EP (1) | EP1845095B1 (fr) |
| JP (2) | JP4492968B2 (fr) |
| KR (1) | KR101268752B1 (fr) |
| CN (1) | CN101103013B (fr) |
| AT (1) | ATE523504T1 (fr) |
| AU (1) | AU2006204258C1 (fr) |
| BR (1) | BRPI0606397B8 (fr) |
| CA (1) | CA2592995C (fr) |
| CY (1) | CY1112467T1 (fr) |
| DK (1) | DK1845095T3 (fr) |
| ES (1) | ES2369030T3 (fr) |
| HK (1) | HK1112239A1 (fr) |
| HR (1) | HRP20110791T1 (fr) |
| ME (1) | ME01324B (fr) |
| MX (1) | MX2007008285A (fr) |
| NO (1) | NO341129B1 (fr) |
| NZ (1) | NZ556342A (fr) |
| PL (1) | PL1845095T3 (fr) |
| PT (1) | PT1845095E (fr) |
| RS (1) | RS52066B (fr) |
| RU (1) | RU2387649C2 (fr) |
| SI (1) | SI1845095T1 (fr) |
| TW (1) | TW200637839A (fr) |
| WO (1) | WO2006073197A1 (fr) |
| ZA (1) | ZA200706021B (fr) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| MX2008014512A (es) * | 2006-05-19 | 2008-11-27 | Taisho Pharma Co Ltd | Compuesto de c-fenil glucitol para el tratamiento de diabetes. |
| JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| JP5152519B2 (ja) * | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | Ｃ−フェニル１−チオグルシト−ル化合物 |
| JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| US20080027014A1 (en) * | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| EP2072522A4 (fr) * | 2006-10-13 | 2010-01-06 | Chugai Pharmaceutical Co Ltd | Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète |
| AU2007332476A1 (en) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-D-glucitol derivative |
| US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
| US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| DK2064222T3 (da) | 2007-04-02 | 2014-07-21 | Theracos Inc | Benzyliske glycosid-derivater og fremgangsmåder til anvendelse deraf |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| RU2497526C2 (ru) * | 2007-08-23 | 2013-11-10 | Теракос, Инк. | Производные бензилбензола и способы их применения |
| WO2009035969A1 (fr) * | 2007-09-10 | 2009-03-19 | Janssen Pharmaceutica N.V. | Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt |
| JP2009107997A (ja) * | 2007-10-31 | 2009-05-21 | Taisho Pharmaceutical Co Ltd | （１ｓ）−１，５−アンヒドロ−１−［５−（４−エトキシベンジル）−２−メトキシ−４−メチルフェニル］−１−チオ−ｄ−グルシトールの結晶形とその製造方法 |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| CN102105153B (zh) | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Sglt2抑制剂的医药用途和含该抑制剂的组合物 |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| SG193168A1 (en) * | 2008-08-22 | 2013-09-30 | Theracos Inc | Processes for the preparation of sglt2 inhibitors |
| BRPI0918841B8 (pt) * | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
| JP2010180143A (ja) * | 2009-02-03 | 2010-08-19 | Taisho Pharmaceutical Co Ltd | ４−（置換ベンジル）−２−ハロフェノール誘導体の製造法 |
| AU2014221222B2 (en) * | 2009-04-16 | 2016-04-28 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical compositions |
| KR20150046382A (ko) | 2009-04-16 | 2015-04-29 | 다이쇼 세이야꾸 가부시끼가이샤 | 제약 조성물 |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| EP2451797B1 (fr) | 2009-07-10 | 2013-04-03 | Janssen Pharmaceutica, N.V. | Procédé de cristallisation pour le 1-(bêta -D-glucopyranosyl)-4-méthyl-3-[5-(4-fluorophényl)-2-thiènylméthyl] benzène |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011047113A1 (fr) * | 2009-10-14 | 2011-04-21 | Janssen Pharmaceutica Nv | Procédé de préparation de composés utiles comme inhibiteurs de sglt2 |
| ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| CN108354930A (zh) | 2010-05-11 | 2018-08-03 | 詹森药业有限公司 | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂 |
| WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
| WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012025857A1 (fr) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2) |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| HUE030116T2 (en) | 2011-04-13 | 2017-04-28 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as inhibitors of SGLT2 |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| KR101576589B1 (ko) * | 2011-06-01 | 2015-12-10 | 주식회사 녹십자 | Sglt2 억제제로서의 신규한 다이페닐메탄 유도체 |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| SG11201406080VA (en) | 2012-03-28 | 2014-11-27 | Fujifilm Corp | SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE |
| WO2013152476A1 (fr) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Procédé de préparation d'inhibiteurs de sglt2 benzylbenzène |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| EP3184112B1 (fr) | 2012-08-13 | 2020-12-23 | FUJIFILM Corporation | INTERMÉDIAIRE DE SYNTHÈSE DE CYTOSINE 1- (2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL) |
| SG11201501510SA (en) * | 2012-08-30 | 2015-04-29 | Taisho Pharmaceutical Co Ltd | Combinations of sglt2 inhibitors and antihypertensive drugs |
| CN103864737B (zh) * | 2012-12-17 | 2016-08-17 | 天津药物研究院 | 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途 |
| EP3246324B1 (fr) * | 2012-12-17 | 2021-08-25 | Tianjin Institute of Pharmaceutical Research | Derive de phenyl-c-glucoside contenant une structure de desoxyglucose, son procede de preparation et ses utilisations |
| JP6353054B2 (ja) * | 2013-09-09 | 2018-07-04 | ヤンジェン セラピューティクス カンパニー リミテッド | Ｃ−アリールグルコシド誘導体、その製造方法およびその医薬適用 |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| CN106061959B (zh) | 2014-02-18 | 2018-11-09 | 富士胶片株式会社 | 四氢噻吩骨架型糖化合物的制造方法及四氢噻吩骨架型糖化合物 |
| JP6204223B2 (ja) * | 2014-02-19 | 2017-09-27 | 富士フイルム株式会社 | チオピラノース化合物等の製造方法 |
| TWI678373B (zh) | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | 硫代核苷衍生物或其鹽及醫藥組合物 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| CN109641009B (zh) | 2016-08-31 | 2021-12-31 | 富士胶片株式会社 | 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒 |
| JP2019531320A (ja) | 2016-10-19 | 2019-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｓａｏ／ｖａｐ−１阻害剤とｓｇｌｔ２阻害剤とを含む組合せ、その使用 |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| CN107857753A (zh) * | 2017-12-04 | 2018-03-30 | 威海贯标信息科技有限公司 | 一种鲁格列净新晶型 |
| MX2018002611A (es) | 2018-01-29 | 2019-07-30 | Fujifilm Corp | Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar. |
| US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
| JP7217875B2 (ja) * | 2018-09-21 | 2023-02-06 | 国立大学法人 琉球大学 | 血液がんの予防及び／又は治療剤 |
| WO2020151621A1 (fr) * | 2019-01-24 | 2020-07-30 | 北京盈科瑞创新药物研究有限公司 | Composé, son procédé de préparation et ses applications médicales |
| CN111471032B (zh) * | 2019-01-24 | 2023-08-01 | 北京盈科瑞创新药物研究有限公司 | 一种糖苷类衍生物的合成方法及其中间体和应用 |
| CN111840271B (zh) * | 2019-04-25 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种糖苷类衍生物新用途 |
| WO2020151623A1 (fr) * | 2019-01-24 | 2020-07-30 | 北京盈科瑞创新药物研究有限公司 | Composé, procédé de préparation et les applications médicales de son intermédiaire |
| WO2020151620A1 (fr) * | 2019-01-24 | 2020-07-30 | 北京盈科瑞创新药物研究有限公司 | Composé, son procédé de préparation et son utilisation en tant qu'intermédiaire de médicament |
| CN111471031B (zh) * | 2019-01-24 | 2023-05-16 | 北京盈科瑞创新药物研究有限公司 | 一种糖苷类衍生物及其制备方法和应用 |
| CN111471040B (zh) * | 2019-01-24 | 2023-06-02 | 北京盈科瑞创新药物研究有限公司 | 一种糖苷类衍生物的合成方法及其中间体和应用 |
| US20230310462A1 (en) | 2020-09-02 | 2023-10-05 | Laboratorios Silanes S.A. De C.V. | Combination drug for the control and management of type 2 diabetes mellitus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES475100A1 (es) * | 1977-11-21 | 1979-12-01 | Hoechst Ag | Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos |
| US5773663A (en) * | 1996-05-01 | 1998-06-30 | American Cyanamid Company | Fungicidal methods, compounds and compositions containing benzophenones |
| CZ294096B6 (cs) * | 1995-01-20 | 2004-10-13 | Americanácyanamidácompany | Benzofenonové sloučeninyŹ způsob jejich výrobyŹ fungicidní prostředky s jejich obsahem a způsob ochrany rostlin |
| CA2190699A1 (fr) * | 1995-12-08 | 1997-06-09 | Johannes Aebi | Amines tertiaires |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| TWI254635B (en) * | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| BR0310006A (pt) * | 2002-08-09 | 2005-02-15 | Taisho Pharmaceutical Co Ltd | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos |
| PL1980560T3 (pl) | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | Pochodne C-glikozydowe do leczenia cukrzycy |
| JPWO2004089967A1 (ja) | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| JP5152519B2 (ja) * | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | Ｃ−フェニル１−チオグルシト−ル化合物 |
| AU2007332476A1 (en) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-D-glucitol derivative |
-
2006
- 2006-01-09 TW TW095100784A patent/TW200637839A/zh unknown
- 2006-01-10 ZA ZA200706021A patent/ZA200706021B/xx unknown
- 2006-01-10 SI SI200631139T patent/SI1845095T1/sl unknown
- 2006-01-10 KR KR1020077013857A patent/KR101268752B1/ko active IP Right Grant
- 2006-01-10 PL PL06711505T patent/PL1845095T3/pl unknown
- 2006-01-10 CN CN2006800019158A patent/CN101103013B/zh active Active
- 2006-01-10 NZ NZ556342A patent/NZ556342A/en unknown
- 2006-01-10 JP JP2006550913A patent/JP4492968B2/ja active Active
- 2006-01-10 DK DK06711505.5T patent/DK1845095T3/da active
- 2006-01-10 EP EP06711505A patent/EP1845095B1/fr active Active
- 2006-01-10 PT PT06711505T patent/PT1845095E/pt unknown
- 2006-01-10 BR BRPI0606397A patent/BRPI0606397B8/pt active IP Right Grant
- 2006-01-10 AT AT06711505T patent/ATE523504T1/de active
- 2006-01-10 ES ES06711505T patent/ES2369030T3/es active Active
- 2006-01-10 RU RU2007130089/04A patent/RU2387649C2/ru active
- 2006-01-10 MX MX2007008285A patent/MX2007008285A/es active IP Right Grant
- 2006-01-10 WO PCT/JP2006/300135 patent/WO2006073197A1/fr active Application Filing
- 2006-01-10 ME MEP-2011-198A patent/ME01324B/fr unknown
- 2006-01-10 CA CA2592995A patent/CA2592995C/fr active Active
- 2006-01-10 AU AU2006204258A patent/AU2006204258C1/en active Active
- 2006-01-10 US US11/794,498 patent/US7910619B2/en active Active
- 2006-01-10 RS RS20110517A patent/RS52066B/en unknown
-
2007
- 2007-08-02 NO NO20074012A patent/NO341129B1/no unknown
-
2008
- 2008-07-07 HK HK08107451.9A patent/HK1112239A1/xx unknown
-
2009
- 2009-10-30 JP JP2009251475A patent/JP5187592B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-30 US US12/982,343 patent/US8017792B2/en not_active Expired - Fee Related
-
2011
- 2011-10-28 HR HR20110791T patent/HRP20110791T1/hr unknown
- 2011-11-22 CY CY20111101130T patent/CY1112467T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110791T1 (hr) | Derivati 1-tio-d-glucitola | |
| ES2394838T3 (es) | Análogos 12-ARIL de prostaglandinas | |
| EP0749306A1 (fr) | Composés et méthodes de traitement de troubles à caractère cardio-vasculaire, inflammatoire et immunitaire | |
| RU2126791C1 (ru) | Производные гидроксамовой кислоты, способ их получения и фармацевтическая или ветеринарная композиция на их основе | |
| JP5676687B2 (ja) | 眼の疾患及び障害治療用のアミン誘導体化合物 | |
| EP2928476B1 (fr) | Composés, compositions et procédés utilisant des antagonistes d'e-sélectine pour la mobilisation de cellules hématopoïétiques | |
| SK78998A3 (en) | Alpha-substituted arylsulphonamido hydroxamic acids as tnf-alpha and matrix metalloproteinase inhibitors | |
| UA75906C2 (uk) | Похідні n-(арилсульфоніл)бета-амінокислот, які містять заміщену амінометильну групу, спосіб їх отримання та фармацевтична композиція, що містить їх | |
| AU2010270797A1 (en) | TOFA analogs useful in treating dermatological disorders or conditions | |
| KR20150126043A (ko) | 안과 질환 및 장애 치료용 치환된 ３-페닐프로필아민 유도체 | |
| WO2011091276A1 (fr) | Chlorocyclopentanols substitués thérapeutiques | |
| JP2011518833A (ja) | 治療剤としての置換ガンマラクタム | |
| WO2021097057A1 (fr) | Hétéroarylaminosulfonamides à 5 chaînons pour le traitement d'états à médiation par une activité cftr déficiente | |
| CN112159401B (zh) | 偏向性激动剂及其医药用途 | |
| CA3148244A1 (fr) | Compose d'uree pour antagoniser le recepteur lpa1 | |
| CN107936022A (zh) | 黄嘌呤类lsd1抑制剂及其制备方法和应用 | |
| AU2002220735B2 (en) | Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain | |
| TWI411438B (zh) | 具有前列腺素活性之經取代環戊烷 | |
| EP0650485B1 (fr) | 2,5-diaryle tetrahydro-thiophenes, -furanes et analogues utilises dans le traitement de troubles inflammatoires et immuns | |
| EP3169666B1 (fr) | Dérivés d'aza-spiro(4.5) décane substitués | |
| JP2011510009A (ja) | 緑内障、高眼圧、禿頭症及び脱毛症の治療用ベータラクタム | |
| WO2013161980A1 (fr) | Dérivé de cyclohexanediamide et son utilisation à des fins médicales | |
| JP2011515409A (ja) | 治療用化合物 | |
| WO2009140205A2 (fr) | Cyclopentanes substitués à visée thérapeutique | |
| CN105801464B (zh) | 吡咯酰胺类化合物及其制备方法与用途 |